Evaluation of the clinical significance of RNase III enzyme DROSHA in pediatrics acute lymphocytic leukemia.

Abstract

Acute lymphocytic leukemia (ALL) is one of the subtypes of leukemia; it is one of the leading causes of malignancy and morbidity and childhood mortality. This study examined the dysregulation of DROSHA and its clinical implications in ALL. In the case-control investigation, we have included 140 samples, consisting of 70 peripheral whole blood samples diagnosed with ALL and 70 age and sex-matched healthy children, to assess the level of expression of DROSHA mRNA between two groups. Quantitative Real-Time PCR was used to establish the level of DROSHA gene expression in the patients and controls. The results revealed that DROSHA was overexpressed in patients compared with controls (p < 0.001). There were no major differences between DROSHA expression and demographic factors and clinicopathological parameters (p > 0.001). The finding of the study revealed that DROSHA expression in ALL patients is significantly up-regulated; which is suggesting that may be served as a critical role in the pathogenesis of ALL. Also, DROSHA will possibly be utilized as a novel therapeutic target for ALL patients within the future.